Amortized Payments For High-Cost Drugs Won't Work, Insurer CEOs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
The idea raised by health policy experts that high-cost drugs could be paid for in installments over a number of years doesn't appeal to insurance executives at recent conference.
You may also be interested in...
Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.